News & Events

Swanbridge Capital invests in IPaDiC

Swanbridge Capital announced it invested in IPaDiC, a private company developing an implantable insulin pump for diabetes type 1 patients with an insulin resistance.

Abegaill successfully closes seed funding round

Abegaill B.V. announces the successfully closing of a seed funding round. This funding is provided by Swanbridge Capital, a Dutch life science venture capital fund, and Leander Healthcare, a Benelux medtech innovation provider.

Swanbridge Capital leads investment round into FABPulous

Swanbridge Capital, a Dutch Life Science Venture Capital fund, today announced its investment in FABPulous B.V., a Dutch start-up company focused on the development of a new diagnostic tool that quickly distinguishes whether patients with chest pains are at urgent risk of a heart attack. Swanbridge Capital co-led the investment round together with Health Innovations.

Launch of €6.5 million Life Sciences Fund

Swanbridge Capital today announced the launch and closing of its first life science fund. The fund, with a size of €6.5 million, will invest in early stage life sciences ventures that require capital to fund their first Proof of Concept experiments.

Meet us at

Healthy Funding

June 28 – Rotterdam

 

Past events

Innovation for Health

February 1 – Rotterdam

 

Swanbridge Capital
Brainpark II - Building XI
Lichtenauerlaan 40
3062 ME Rotterdam

info@swanbridgecapital.nl

© 2016 Swanbridge Capital